# US 2022/0009970 A1 · Immunogenic composition against avian influenza virus h5 subtype

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009970 A1
- Document ID: US20220009970A1
- Status: Published application
- Kind: A1
- Application number: 17/291,924
- Filed: 2019-11-05
- Published: 2022-01-13
- Earliest claimed: 2018-11-06
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Applicants: Boehringer Ingelheim Vetmedica GmbH
- Inventors: Egbert Siegfried MUNDT; Xiaoping CUI; Zenglei HU
- Web page: https://patentgrep.com/patent/US20220009970A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/11: Orthomyxoviridae, e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- G01N 33/56983: {Viruses}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C12N 2710/14043: viral genome or elements thereof as genetic vectore
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2760/16163: by chemical treatment
- C12N 2760/16171: Demonstrated in vivo effect
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.

## Claims

### Claim 1

An immunogenic composition comprising a hemagglutinin protein of avian influenza virus HS subtype, wherein the hemagglutinin protein comprises:
one or more amino acid residues selected from the group consisting of: 61D, 87I, 99A, 102A, 110N, 136S, 140D, 149S, 156T, 157P, 170N, 172T, 178R, 190V, 191L, 200A, 226V, 243D, 268Y, 279A and 298I;
with numbering with reference to amino acid residues as set forth in SEQ ID NO: 5.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the hemagglutinin protein comprises:
(a) amino acid residues 61D, 87I, 99A, 102A, 110N, 120N, 136S, 140D, 149S, 155N, 156T, 157P, 170N, 172T, 178R, 190V, 191L, 200A, 223N, 226V, 243D, 268Y, 279A and 298I;
(b) an amino acid sequence as set forth in SEQ ID NO: 6; or
(c) an amino acid sequences as set forth in SEQ ID NO: 5.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The immunogenic composition of claim 1, wherein the hemagglutinin protein is contained in a cell culture, and the cell culture is prepared by culturing cells containing an expression vector capable of expressing the hemagglutinin protein as defined in claim 1.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The immunogenic composition of claim 5, wherein the nucleic acid molecule is set forth in SEQ ID NO: 10 or SEQ ID NO: 11.

### Claim 8

(canceled)

### Claim 9 (depends on 5)

The immunogenic composition of claim 5, wherein the expression vector is a baculovirus, and the cells are insect cells.

### Claim 10 (depends on 5)

The immunogenic composition of claim 5, wherein the cell culture is subjected to an inactivation step, preferably an inactivation step by binary ethyleneimine.

### Claim 11 (depends on 5)

The immunogenic composition of claim 5, wherein the immunogenic composition comprises a portion or all of the cell culture.

### Claim 12 (depends on 2)

The immunogenic composition of claim 2, wherein the immunogenic composition further comprises an adjuvant.

### Claim 13 (depends on 11)

The immunogenic composition of claim 11, wherein the adjuvant is a water-in-oil emulsion.

### Claim 14 (depends on 1)

The immunogenic composition of claim 1, wherein the immunogenic composition is administered in a single-dose administration or multiple doses administration; and/or the immunogenic composition is administered subcutaneously or intramuscularly; and and/or the immunogenic composition is to be administered to an animal at 1 day or age or older, at 7 day of age or older, at 10 day of age or older, at 15 day of age or older, or at 21 day of age or older.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method of differentiating animals naturally infected with an avian influenza virus from animals vaccinated with the immunogenic composition of claim 1, comprising:
(a) analyzing a sample of an animal in an immuno test and/or genomic analytical test for the presence of an avian influenza marker which is specific for the immunogenic composition but not present in the naturally infected animal, wherein the immuno test is an enzyme immunoassay or enzyme linked immunosorbent assay;
(b) determining whether the sample is positive or negative for the avian influenza marker, and
(c) correlating the test results with the status of the tested animal, wherein an animal that is positive for the avian influenza marker is an animal that is vaccinated with the immunogenic composition of claim 1.

### Claim 19

(canceled)

### Claim 20 (depends on 5)

The immunogenic composition of claim 5, wherein the immunogenic composition further comprises an adjuvant.

### Claim 21 (depends on 20)

The immunogenic composition of claim 20, wherein the adjuvant is a water-in-oil emulsion.

### Claim 22 (depends on 6)

The immunogenic composition of claim 6, wherein the immunogenic composition further comprises an adjuvant.

### Claim 23 (depends on 22)

The immunogenic composition of claim 22, wherein the adjuvant is a water-in-oil emulsion.

### Claim 24 (depends on 7)

The immunogenic composition of claim 7, wherein the expression vector is a baculovirus, and the cells are insect cells.

### Claim 25 (depends on 7)

The immunogenic composition of claim 7, wherein the cell culture is subjected to an inactivation step, preferably an inactivation step by binary ethyleneimine.

### Claim 26 (depends on 7)

The immunogenic composition of claim 7, wherein the immunogenic composition comprises a portion or all of the cell culture.

### Claim 27 (depends on 2)

The immunogenic composition of claim 2, wherein the hemagglutinin protein is contained in a cell culture, and the cell culture is prepared by culturing cells containing an expression vector capable of expressing the hemagglutinin protein as defined in claim 2.

### Claim 28 (depends on 2)

The immunogenic composition of claim 2, wherein the immunogenic composition is administered in a single-dose administration or multiple doses administration; and/or the immunogenic composition is to be administered to an animal at 1 day of age or older, at 7 day of age or older, at 10 day of age or older, at 15 day of age or older, or at 21 day of age or older.

### Claim 29 (depends on 2)

A method of differentiating animals naturally infected with an avian influenza virus from animals vaccinated with the immunogenic composition of claim 2, comprising:
(a) analyzing a sample of an animal in an immuno test and/or genomic analytical test for the presence of an avian influenza marker which is not present in the immunogenic composition but present in the naturally infected animal, wherein the immuno test is an enzyme immunoassay or enzyme linked immunosorbent assay,
(b) determining whether the sample is positive or negative for the avian influenza marker, and
(c) correlating the test with the status of the tested animal, wherein an animal that is positive for the avian influenza marker is a naturally infected animal and the animal that is negative for the avian influenza marker is an animal that is vaccinated with the immunogenic composition of claim 2.
